This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Optimer Soars on Antibiotic Data

According to the top-line results from the phase III study announced Monday night, 88% of patients treated with OPT-80 achieved a clinical cure compared to 86% of patients treated with Vancocin.

Patients were treated with OPT-80 twice daily for 10 days. Vancocin was dosed four times daily, also for 10 days. A clinical cure was defined as patients requiring no further therapy for C. diff two days after completing treatment.

A key secondary endpoint of the study measured the recurrence, or relapse rate. Here, too, OPT-80 excelled, with just 15% of patients reporting a recurrence of the C. diff infection four weeks after treatment compared to a 25% recurrence rate reported for patients treated with Vancocin.

Optimer's phase III study was designed to show statistically non-inferior efficacy of OPT-80 compared to Vancocin on both the primary endpoint (cure rate) and the secondary endpoint of recurrence rate. The fact that OPT-80 was numerically superior on both endpoints is a big win for the drug.

Recurrence of C. diff infection in treated patients is a growing problem, so the lower recurrence rate for OPT-80 makes a strong case for using the drug as a first-line treatment.

A second phase III study of OPT-80 in C. diff patients is ongoing with data expected in the second half of 2009. Optimer also said it plans to resurrect partnering discussions for OPT-80. In 2007, an experimental antibiotic from Genzyme (GENZ) failed a closely watched phase III study.

Optimer shares closed Monday at $4.60 prior to the release of the OPT-80 study results. That news sent the stock up 90% to $8.75 in the after-hours session.

Know What You Own: In Tuesday's early trading, other top biotech performers include Genetic Technologies (GENE), Targacept (TRGT), Cytokinetics (CYTK - Get Report) and BioDelivery Sciences (BDSI - Get Report).
At the time of publication, Feuerstein's Biotech Select model portfolio was long Optimer Pharmaceuticals.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
VPHM $49.96 -0.02%
OPTR $0.00 0.00%
BDSI $6.59 5.80%
CYTK $7.02 3.10%
GENE $1.98 0.51%


Chart of I:DJI
DOW 16,912.29 +122.10 0.73%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,791.1520 +42.7910 0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs